M.S. Figueroa Spain

The journey of VEGF inhibition and future perspectives

C. Regillo USA

Transforming treatment in nAMD

M.S. Figueroa Spain C. Regillo USA

Experts in conversation: innovations in drug delivery and the impact on clinical practice

M.S. Figueroa Spain C. Regillo USA

Q&A Session

B.P. Leroy Belgium

Welcome and introduction

A. Daly Ireland

Pathway to diagnosis of an inherited retinal dystrophy (IRD): the patient perspective

C.B. Hoyng The Netherlands

Focusing on referral: getting to know your IRD network

B.P. Leroy Belgium

Genetic counselling: interpreting and evaluating a diagnosis

D. Fischer UK

Notes from a Treatment Center: from referral to follow-up

B.P. Leroy Belgium

Summary and close

A. Loewenstein Israel

Welcome and introduction

S. Sadda USA

The importance of retinal fluid in the management of patients with nAMD

F. Holz Germany

Latest evidence on the treatment of patients with nAMD

Clinical case discussion

Live Q&A

P. Lanzetta Italy

Welcome and introductions

M. Stewart USA

Considering drug dynamics: what is the relevance for clinical practice?

N. Holekamp USA

Fluid in focus: advancing our understanding

N. Eter Germany

Proactive and practical: extending intervals with aflibercept

P. Lanzetta Italy

Expert exchange: practical insights from the clinic

A. Loewenstein Israel

Welcome and ARS questions

S. Wolf Switzerland

Review of EURETINA AMD clinical trends survey data

S. Wolf Switzerland

The AMD treatment burden

R. Tadayoni France

Current and future applications of longer lasting anti-VEGF therapeutics

D. Pieramici USA

Insights and pearls on implantable sustained release technologies

A. Loewenstein Israel

Artificial intelligence (AI) in AMD treatment decision-making

Panel discussion

A. Loewenstein Israel

Final ARS and key takeaway messages

I. Pearce UK

Welcome and introductions

J. Koroblenik France

Early intensive and proactive long-term treatment: delivering on the promise of RCT-like outcomes in the real world

V. Chaudhary Canada

Retinal vascular disease: differentiation in treatment and the view of international guidelines

F. Behar-Cohen France

All in the action: multi-targeting three underlying pathways

I. Pearce UK

Experience from the experts: panel discussion

F. G. Holz Germany

Welcome and ARS questions

F. G. Holz Germany

Review of EURETINA AMD clinical trends survey data

G. Staurenghi Italy

Multi-modal imaging and its importance in diagnosing and monitoring AMD

M. Zinkernagel Switzerland

Wet AMD treatments: outcome goals

J. Monés Spain

Wet AMD treatments: protocols and therapy decisions

P. Kaiser USA

Panel discussion: anti-VEGF safety concerns in a real-world setting

F. G. Holz Germany

Final ARS and key takeaway messages

R. Tadayoni France

Introduction

S. Rizzo Italy

How the vitreous cutter with bevel tip changed my vitreoretinal surgery

M. Ruiz Spain

Atraumatic ILM peeling: innovation in Macular Hole surgery

D. Chow Canada

My first 3 years with the integrated Digital Assisted Surgery platform

R. Tadayoni France P. Saharinen Finland

Experts in conversation:

- impact of anti-VEGF therapies and future perspectives

- advancing our understanding of the angiopoietin pathway

- from the bench: the role of Ang-2 in retinal disease mechanisms

- from the clinic: Ang-2 in the retina

R. Tadayoni France P. Saharinen Finland

Live discussion with the experts

J. Monés Spain

Case studies in GA

U. Chakravarthy UK

Exploring the unmet need in GA

U. Chakravarthy UK

The role of complement in GA

J. Monés Spain

Future pathways: The potential role of C3 in GA treatment

N. Bressler USA

Welcome and introduction

N. Bressler USA

Decentralized clinical trials

T. Y. Wong Singapore

Artificial intelligence and tele-ophthalmology in the post-COVID19 era

R. Hess Canada

Advances in digital therapies in ophthalmology

P. Mitchell USA

Welcome and introduction

Panelists

The experts’ viewpoint

C. Creuzot-Garcher France

Diabetic eye disease: treat the eye or the body?

A. Tufail UK

DR screening programs: preventing vision loss?

P. Schlottmann Argentina

DME management: what have we learnt?

Panelists

How will COVID influence the future management of diabetic eye disease?

P. Mitchell USA

Conclusions

J. Sahel USA

Clinical overview, epidemiology and unmet need

B. Lam USA

Clinical diagnostics: accurate, timeline diagnosis of patients with IRDs

B. LeRoy Belgium

Confirming IRDS: genetic testing

D. Fischer UK

Anatomical considerations for administration of subretinal injection

L. Wu Costa Rica

Concept and reasons of the SubLiminal Laser approach - should we treat the fovea?

C. Kiire UK

Subliminal Laser for predominantly non-center involving DME?

A. Filloy Spain

Subliminal Laser for center involving DME: when and how?

M. Gawęcki Poland

Transfoveal SubLiminal laser treatment of CSC

V. Chong UK

Subliminal laser for AMD